Table 1 Demographic, clinical and post-mortem characteristics of the three groups
From: Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study
Groups | Control n = 32 | AD n = 44 | iAD n = 16 | |
|---|---|---|---|---|
Gender | 17F:15M | 28F:16M | 7F:9M | |
Age of Death (years, mean ± SD) | 84 ± 7 | 80 ± 6 | 79 ± 8 | |
Age of AD onset (years, mean ± SD) | n/a | 70 ± 7 | 67 ± 8 | |
Duration of AD (years, mean ± SD) | n/a | 10 ± 3 | 12 ± 4 | |
Braak Stage | 0-II: 29 III-IV: 3 V-VI: 0 | 0-II: 0 III-IV: 4 V-VI: 40 | 0-II: 0 III-IV: 1 V-VI: 15 | |
APOE genotype | ε4/− | 3/28 (10.7%) | 13/38 (34.2%) | 6/10 (60.0%) |
ε4/ε4 | 1/28 (3.6%) | 9/38 (23.7%) | 3/10 (30.0%) | |
Post-mortem delay (hours, mean ± SD) | 42 ± 23 | 42 ± 26 | 22 ± 25 | |